Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Sarepta Therapeutics (SRPT)

Sarepta Therapeutics (SRPT)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 8,320,489
  • Shares Outstanding, K 74,543
  • Annual Sales, $ 301,030 K
  • Annual Income, $ -361,920 K
  • 60-Month Beta 2.27
  • Price/Sales 23.30
  • Price/Cash Flow N/A
  • Price/Book 8.40

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 17 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/19
See More
  • Average Estimate -1.89
  • Number of Estimates 9
  • High Estimate -1.66
  • Low Estimate -2.18
  • Prior Year -2.05
  • Growth Rate Est. (year over year) +7.80%

Price Performance

See More
Period Period Low Period High Performance
1-Month
108.54 +8.65%
on 01/27/20
134.57 -12.37%
on 01/10/20
-11.84 (-9.12%)
since 12/27/19
3-Month
81.43 +44.82%
on 10/31/19
138.79 -15.03%
on 12/13/19
+30.20 (+34.42%)
since 10/28/19
52-Week
72.05 +63.68%
on 09/26/19
158.80 -25.74%
on 07/15/19
+1.90 (+1.64%)
since 01/28/19

Most Recent Stories

More News
Bragar Eagel & Squire is Investigating Certain Officers and Directors of Cardinal Health, CURO Group, Sarepta, and PG&E Corporation and Encourages Investors to Contact the Firm

Bragar Eagel & Squire, P.C., a nationally recognized shareholder law firm, is investigating certain officers and directors of Cardinal Health, Inc. (NYSE: CAH), CURO Group Holdings Corp. (NYSE: CURO),...

CAH : 53.80 (+0.79%)
CURO : 10.43 (+2.15%)
SRPT : 117.93 (+5.65%)
PCG : 14.95 (+6.48%)
Sarepta Therapeu Has Returned 46.6% Since SmarTrend Recommendation (SRPT)

SmarTrend identified an Uptrend for Sarepta Therapeu (NASDAQ:SRPT) on October 4th, 2019 at $87.38. In approximately 4 months, Sarepta Therapeu has returned 46.59% as of today's recent price of $128.08....

SRPT : 117.93 (+5.65%)
Sarepta Therapeu Set to Possibly Rebound After Yesterday's Selloff of 1.17%

Sarepta Therapeu (NASDAQ:SRPT) traded in a range yesterday that spanned from a low of $126.01 to a high of $128.62. Yesterday, the shares fell 1.2%, which took the trading range below the 3-day low of...

SRPT : 117.93 (+5.65%)
CytoDyn Appoints Alan Timmins as New Independent Director and Chair of the Audit Committee

CytoDyn Inc. (OTC.QB: CYDY), ("CytoDyn" or the "Company"), a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications,...

CYDY : 1.2000 (+4.80%)
SRPT : 117.93 (+5.65%)
Are Options Traders Betting on a Big Move in Sarepta (SRPT) Stock?

Investors need to pay close attention to Sarepta (SRPT) stock based on the movements in the options market lately.

SRPT : 117.93 (+5.65%)
Sarepta Therapeu Shares Up 47.5% Since SmarTrend's Buy Recommendation (SRPT)

SmarTrend identified an Uptrend for Sarepta Therapeu (NASDAQ:SRPT) on October 4th, 2019 at $87.38. In approximately 3 months, Sarepta Therapeu has returned 47.48% as of today's recent price of $128.86....

SRPT : 117.93 (+5.65%)
Muscular Dystrophy Collaboration Aims to Correct Muscle Stem Cells' DNA

Harvard University stem cell researchers led by Amy Wagers, PhD, are embarking on a major study of Duchenne muscular dystrophy (DMD). Supported by research funding from Sarepta Therapeutics, under a multi-year...

SRPT : 117.93 (+5.65%)
Sarepta Therapeutics Appoints Renowned Biotech Executive John C. Martin to its Board of Directors

Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, announced that it has appointed John C. Martin, Ph.D., to its Board of Directors, effective today....

GILD : 64.36 (+0.83%)
SRPT : 117.93 (+5.65%)
Applied Genetic Stock Up on Favorable Eye Therapy Study Data

Applied Genetic's (AGTC) gene therapy candidate shows promise in an early-stage study to treat X-linked retinitis pigmentosa, a rare eye disorder.

AGTC : 7.27 (-7.51%)
SRPT : 117.93 (+5.65%)
RGNX : 43.53 (+0.39%)
SLDB : 3.43 (-1.15%)
Technological Advancements Expand Biopharmaceuticals' Production Capabilities

The biopharmaceutical industry is driven by multiple factors, all while rapidly evolving in the digital era. The need to engineer drugs to treat emerging diseases, an increase in the geriatric population...

NNVC : 8.40 (-46.84%)
GILD : 64.36 (+0.83%)
SRPT : 117.93 (+5.65%)
ABBV : 83.77 (-0.30%)
IONS : 59.91 (+1.39%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Buy with a Average short term outlook on maintaining the current direction.

See More Share

Trade SRPT with:

Business Summary

Sarepta Therapeutics, Inc. focuses on the discovery and development of RNA-based therapeutics for the treatment of rare and infectious diseases. The Company's diverse pipeline includes its lead program eteplirsen, for Duchenne muscular dystrophy. Sarepta Therapeutics, Inc., formerly known as AVI BioPharma,...

See More

Key Turning Points

2nd Resistance Point 121.57
1st Resistance Point 119.75
Last Price 117.93
1st Support Level 114.33
2nd Support Level 110.73

See More

52-Week High 158.80
Fibonacci 61.8% 125.66
Last Price 117.93
Fibonacci 50% 115.43
Fibonacci 38.2% 105.19
52-Week Low 72.05

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar